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Abstract
Background: Abnormal expression of SOCS3 has been implicated in myeloproliferative neoplasms, but the role of
SOCS3 in the pathogenesis of leukemia remains largely unknown. Here, we examined the function of SOCS3 in the
growth and chemo-sensitivity of chronic myeloid leukemia (CML) and explored the involved mechanisms.
Methods: Expression levels of SOCS3 in several leukemia cell lines and bone marrow mononuclear cells (BMNCs)
from CML patients were determined using quantitative real-time PCR (qPCR) and Western blotting (WB). The roles
of SOCS3 in the proliferation, apoptosis, and drug resistance of CML cells were examined by clonogenic progenitor
cell assay, flow cytometry, and CCK-8 assay. A detailed analysis of the underlying mechanism of SOCS3 in K562 cells
was performed using the Human HT-12 v4 Expression BeadChip, which has more than 48000 gene probes
including 600 microRNAs (miRNA) probes. The correlation between the mRNA expression of SOCS3 and miR-124-3p
in BMNCs from 30 CML patients was tested by qPCR and analyzed by Pearson correlation and linear regression
analysis. The potential target of miR-124-3p in CML cells was explored using the luciferase reporter assay, qPCR, and
WB. The effect of SOCS3 on the miR-124-3p/B4GALT1 axis was investigated by qPCR, WB, CCK-8 assay, and
tumorigenicity assays in nude mice.
Results: SOCS3 was down-regulated in CML cell lines and most of BMNCs from CML patients, and the expression
level of SOCS3 was associated with the inhibition of cell proliferation and drug resistance of CML cells. Over-
expression of SOCS3 in K562 cells inhibited the expression of leukemia-specific genes and promoted the expression
of some miRNAs, among which miR-124-3p was the highest. SOCS3 over-expression enhanced the expression of
miR-124-3p and vice versa. The mRNA expression of miR-124-3p and SOCS3 in BMNCs from 30 CML patients was
positively correlated. Consistently, the tumor suppressing effects of SOCS3 were partially neutralized by the
miR-124-3p inhibitor. B4GALT1 was downstream of miR-124-3p and regulated by SOCS3/miR-124-3p in vitro.
Furthermore, SOCS3 over-expression could inhibit the growth and B4GALT expression of K562 cells in vivo.
Conclusions: SOCS3/miR-124-3p/B4GALT1 axis plays an important role in the pathogenesis of CML.
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Background
Suppressor of cytokine signaling (SOCS) is a protein fam-
ily of eight members (SOCS1–7 and CIS) that form a clas-
sical negative feedback system to regulate cytokine signal
transduction [1]. By regulating the cytokine-driven STAT
activation pathway, SOCS3 likely has an important role in
development, allergic responses, and tumorigenesis [2–4].
Methylation of the SOCS3 promoter and reduced gene ex-
pression of SOCS3 have been documented in numerous
tumors such as breast cancer, lung cancer, and liver cancer
[5–7]. SOCS3 is highly conserved among vertebrates and
has been considered to be a transcriptional regulator in
the hematopoietic system. SOCS3−/− mice die in utero be-
cause of fetal liver erythrocytosis, and over-expression of
SOCS3 blocks fetal liver erythrocytosis, implying that
SOCS3 plays a critical role in the negative regulation of
hematopoiesis [8, 9].
Evidence suggests a potential role of SOCS3 in the
pathogenesis of leukemia. For example, Capello et al re-
vealed that inactivation of SOCS3 was frequent in Ph-
negative chronic myeloproliferative disorders (CMPD)
[10]. Al-Jamal et al. reported that down-regulation of
SOCS3 was involved in the resistance of CML cells to
imatinib [11]. However, the exact function of SOCS3 in
hematological malignancies remains unclear. A better
understanding of the function and underlying molecular
mechanisms of SOCS3 will contribute to the precision
medicine in the field of CML.
In a previous study, we showed that SOCS3 was im-
portant for lineage commitment of hematopoietic stem
cells to erythroid cells. SOCS3 knock-down increased
the expression of multiple erythroid-specific genes and
inhibited the expression of genes controlling lymphoid
differentiation [12]. In this study, we wanted to
investigate the contribution of SOCS3 in pathogenesis of
CML and further understand the potential underlying
mechanisms of SOCS3. Previous studies suggested dys-
regulation of microRNA (miRNA) networks had been
implicated in hematological malignancies, for example
miR-29a/29b dysregulation played an important role in
myeloid leukemogenesis [13]. So, understanding of
miRNA biology in carcinogenesis could possibly pave
novel routes for anti-cancer therapy [14, 15]. Here, we
found that over-expression of SOCS3 in CML cells in-
duced a transcriptional program enriched for leukemia
suppression factors, including some miRNAs. For ex-
ample, miR-124-3p was obviously up-regulated by
SOCS3 over-expression. In turn, alterations of miR-124-
3p expression levels influenced the effect of SOCS3 on
CML cells. Furthermore, we confirmed that B4GALT1, a
multidrug resistance gene, was the target gene of the
SOCS3/miR-124-3p axis. These findings suggested the
presence of a dysregulated molecular network involving
SOCS3, miR-124-3p, and B4GALT1, which may provide
novel insights into tumor biology and present a useful
target for therapeutic interference of CML under certain
circumstances.
Results
Expression of SOCS3 was dysregulated in CML cells
We measured the expression of SOCS3 by qPCR in a
panel of human leukemia cell lines and primary bone
marrow mononuclear cells (BMNCs) from healthy do-
nors (n = 3). We found that SOCS3 expression was
down-regulated in human leukemia cells, with the low-
est expression levels in K562 cells, indicating that
SOCS3 could be down-regulated in CML (Fig. 1a). We
further analyzed the expression of SOCS3 in BMNCs
Fig. 1 Expression of SOCS3 was dysregulated in CML cells. a Expression
of endogenous SOCS3 was examined by q-PCR in leukemia cell lines
and BMNCs from three healthy donors. β-Actin was served as an
internal control. SOCS3 expression in cells from donor 1 was set as a
standard. Each point represented the mean of three independent
experiments (n= 3).*P< 0.05; compared with standard. b SOCS3
expression in BMNCs from five healthy donors and 15 CML patients
was examined by q-PCR. β-Actin was served as an internal control.
SOCS3 expression in healthy donor 1 was set as a standard. Each point
represented the mean of three independent experiments (n = 3).
*P < 0.05; compared with the healthy donor group. All data were
expressed as the mean ± SD
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from 15 untreated CML patients. We found that com-
pared with healthy donors (n = 5), SOCS3 expression
was significantly down-regulated (which is below the
minimal level of five healthy volunteers) in most of
BMNCs from CML patients (12 of 15) (Fig. 1b). The
protein expression of SOCS3 was also reduced greatly in
CML cell lines and many patients (Additional file 1). All
these findings suggested that expression of SOCS3 was
dysregulated in CML cells.
SOCS3 regulated the growth of CML cells
To investigate the role of SOCS3 in CML cells, the ex-
pression and inference vectors of SOCS3 were stably
transduced into K562 and KU812 cells using the lenti-
viral system. We found that SOCS3 over-expression in-
duced a marked reduction in the number of colonies
and SOCS3 knock-down led to a significant increase in
the number of colonies from K562 cells by the clono-
genic formation assay (Fig. 2a, b). Similar results were
observed in KU812 cells (Fig. 2b). The CCK-8 assay con-
firmed that SOCS3 over-expression markedly inhibited
the growth of K562 and KU812 cells, while SOCS3
down-regulation promoted the proliferation of these
cells when compared with empty or non-targeting
shRNA (shControl) groups (Fig. 2c).
SOCS3 contributed to imatinib-induced apoptosis of CML
cells
We examined SOCS3 expression levels in K562 and
KU812 cells prior to and after imatinib treatment. qPCR
assays demonstrated a marked increase in mRNA levels
of SOCS3 after imatinib treatment in two CML cell
lines. Western blot assays confirmed a marked increase
in the protein levels of SOCS3 after imatinib treatment
(Fig. 3a). We also found that SOCS3 itself could not in-
duce an obvious increase in apoptotic cells when K562
or KU812 cells were transduced with SOCS3 over-
expression vector. However, SOCS3 over-expression
could induce a marked increase in the percentage of
apoptotic cells in the presence of imatinib (Fig. 3b, c).
SOCS3 inhibited the expression of leukemia-specific
genes and promoted a series of miRNAs
To characterize the transcriptional changes caused by
SOCS3, the gene expression profile of K562 was deter-
mined 48 h after SOCS3 over-expression or empty vec-
tor transduction. Total RNA from these cells was
hybridized to an Illumina Human HT-12 v4 expression
bead array. After normalization, the gene expression
profile of two groups was compared using Benjamini
Hochberg FDR values. Ultimately, we identified 296
Fig. 2 SOCS3 regulated the proliferation and clonogenic growth of CML cells. a Representative pictures showing the effects of SOCS3 over-expression or
knock-down on the clonogenic growth of K562 cells. Bar = 50 μm. b Statistical analysis for the number of colonies from CML cells after over-expression
of SOCS3 or shRNA vector were transduced into K562 and KU812 cells. Data represented the mean ± SD from three experiments. c The effect of SOCS3
on cell proliferation was examined by the CCK-8 assay. Data represented the mean ± SD from three experiments (n= 3). *P< 0.05; compared with the
empty; #P< 0.05; compared with shControl
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genes with significant differential expression in K562
cells that over-expressed SOCS3. Among them, 198
genes were up-regulated and 98 genes were down-
regulated. The pathways and genes that significantly
changed were classified as follows: cancer pathways
(EPAS1, CCND1, FGF13), myeloid leukemia pathways
(ZBTB16, KIT, IL13), hematopoietic cell lineage path-
ways (EPOR, GYPA, CD36) and so on (Fig. 4). In
addition, we also found that some miRNAs were signifi-
cantly affected by SOCS3 over-expression and that the
expression of miR-124-3p was the highest in these miR-
NAs (data not shown).
Fig. 3 SOCS3 was up-regulated by imatinib. a The expression of SOCS3 in K562 and KU812 cells was examined by qPCR and western blotting
after they were treated with imatinib for 48 h. β-Actin was served as an internal control. Each value was the mean ± SD of three experiments
(n = 3), *P < 0.05; compared with untreated cells. b Apoptosis of K562 and KU812 cells, which were transduced with SOCS3 over-expression or
empty vectors, were examined by Annexin V staining following treatment with imatinib (48 h). c Statistical analysis of apoptosis in K562 and
KU812 cells after imatinib treatment. Data represented the mean ± SD from three experiments (n = 3). *P < 0.05; compared with cells transduced
with empty vector
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Next, we investigated SOCS3-induced gene expression
alteration in K562 cells using GO analysis (Additional
file 2). The results confirmed that the cancer and
hematopoietic cell development signaling pathways were
mainly associated with responses to over-expression of
SOCS3 in K562 cells.
SOCS3 promoted miR-124-3p expression in CML cells
We further confirmed the effect of SOCS3 on the ex-
pression of miR-124-3p in K562 and KU812 cell lines by
q-PCR. The results showed that SOCS3 over-expression
enhanced the expression of miR-124-3p, and that
SOCS3 knock-down inhibited the expression of miR-
124-3p in both cell lines (Fig. 5 a, b). In addition,
imatinib treatment resulted in a significant increase of
miR-124-3p in CML cell lines, while up-regulation of
miR-124-3p induced by imatinib was inhibited by SOCS3
knock-down in K562 and KU812 cells (Fig. 5c).
Next we explored the correlation between SOCS3 and
miR-124-3p in BMNCs from CML patients (n = 30). The
levels of SOCS3 and miR-124-3p were measured and
normalized. As shown in Fig. 5d, when the relative ex-
pression levels of miR-124-3p were plotted against that
of SOCS3 in each patient, a significant positive
correlation was found (miR-124-3p vs. SOCS3: R = 0.86,
P < 0.05).
We next investigated whether SOCS3 regulated CML
cell function by up-regulating miR-124-3p. MiR-124-3p
inhibitor and negative control were transduced into
K562 and KU812 cells that were stably transduced by
SOCS3 over-expression vector. Growth capacity was
compared with cells transduced with empty expression
vector. As expected, the cell proliferation assay and clo-
nogenic assay showed that the miR-124-3p inhibitor par-
tially neutralized the inhibiting effects of SOCS3 (Fig. 6).
B4GALT1 is a target of miR-124-3p in CML cells
Next, we searched for potential genes regulated by miR-
124-3p in leukemogenesis. Using TargetScan and mi-
Randa online search programs, we identified B4GALT1
as a potential target of miR-124-3p. A matched sequence
was found at the nts 2089–2096 region of B4GALT1
mRNA 3’UTR (Fig. 7a).
To confirm that miR-124-3p targets the 3‘UTR region
of B4GALT1 in CML cells, HEK293 cells were co-
transduced with miR-124-3p expression or control
vector along with either the full-length 3‘UTR of
B4GALT1(Luci-B4GALT1) or mutated Luci-B4GALT1
Fig. 4 The effect of SOCS3 expression on the gene expression profile of K562 cells. Heat-map showing gene expression profiles in K562 cells 48 h
after transduction with SOCS3 over-expression or empty vectors. Each kind of sample was repeated three times by microarray (n = 3)
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reporter vectors bearing deletions of the 3‘UTR target
regions (△Luci-B4GALT1) (Fig. 7b). We found that lucif-
erase activity of HEK293 cells was significantly decreased
after co-transduction of miR-124-3p expression vector
and a 3‘UTR vector containing the B4GALT1/miR-124-
3p target sequence (Fig. 7c).
Moreover, we over-expressed or inhibited the expres-
sion of miR-124-3p in K562 and KU812 cells and deter-
mined the endogenous expression of B4GALT1 at both
the protein and mRNA level. We found that the mRNA
level of B4GALT1 was not significantly affected by miR-
124-3p in comparison with the control in both K562
and KU812 cells (Fig. 7d, e). However, B4GALT1 protein
was markedly reduced after transduction with miR-124-
3p expression vector, and vice versa (Fig. 7f ). These data
indicated that B4GALT1 was the target gene of miR-
124-3p in CML cells, and miR-124-3p suppressed
B4GALT1 gene expression at the post-transcriptional
level.
B4GALT1 was regulated by the SOCS3/miR-124-3p axis
The expression of B4GALT1 protein was examined in
K562 cells after the expression or inference vectors of
SOCS3 were stably transduced into them. The results
showed that B4GALT1 expression was inhibited by
SOCS3 over-expression and promoted by SOCS3 knock
down in vitro (Fig. 8a). We further found that SOCS3-
induced down-regulation of B4GALT1 was attenuated
by the presence of the miR-124-3p inhibitor (Fig. 8b).
To investigate the impact of B4GALT1 on SOCS3-
induced chemo-sensitivity promotion in leukemia cells,
K562 cells which stably over-expressed SOCS3 were
transduced with the B4GALT1 expression vector or its
negative control and then we examined apoptosis ratios
of K562 cells in different groups after imatinib treat-
ment. We found that ectopic expression of B4GALT1
significantly abrogated increasing chemo-sensitivity in-
duced by SOCS3 over-expression in K562 cells (Fig. 8c).
Furthermore, K562 cells (5 × 106), which were trans-
duced with SOCS3 over-expressing or empty vector,
were inoculated into 25-g male nude mice subcutane-
ously (n = 8). The tumor formations were observed
4 weeks after inoculation. We found the weight of tu-
mors in the SOCS3 over-expression group was signifi-
cantly lower than that of the empty vector groups
(Fig. 8d). Finally, tumor tissues were collected and sec-
tioned. Immuno-histological examination was carried
out using an antibody raised against B4GALT1. Fewer
B4GALT1-positive cells were observed in the tumors of
SOCS3 over-expressing group (Fig. 8e).
Discussion
In this study, we explored the function and involved
mechanisms of SOCS3 in the pathophysiology of CML.
Fig. 5 SOCS3 regulated the expression of miR-124-3p in CML cells. The relative mRNA levels of SOCS3 or miR-124-3p in K562 and KU812 cells
were analyzed by q-PCR after SOCS3 over-expression (a) or knock-down (b). Each value was the mean ± SD of three experiments (n = 3),*P < 0.05;
compared with standard. c Relative mRNA levels of miR-124-3p in K562 and KU812 cells that were stably transduced with shSOCS3 or shControl
vector were examined at 48 h following imatinib treatment. Results were normalized to untreated cells. RNU6-2 was served as an internal control.
Each value was the mean ± SD of three experiments (n = 3), *P < 0.05; compared with shControl. d Statistically significant correlation between
miR-124-3p and SOCS3 expression was observed by Pearson’s method. The y-axis or x-axis represented the relative mRNA levels of miR-124-3p or
SOCS3 in BMNCs from 30 CML patients, which were normalized against internal control RNU6-2 or β-Actin. Each point represented the mean of
three independent experiments (n = 3). Data are expressed as the mean ± SD
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Firstly, we found that both mRNA and protein expres-
sion of SOCS3 were down-regulated in CML cell lines
and most of samples from CML patients. Sakai et al. ob-
served a large variation of SOCS3 expression in different
patients [16]; here, we also found the significant differ-
ence of SOCS3 expression in different patients which
implied SOCS3 may be used as an index for CMLpreci-
sion diagnosis in the future.
Previous studies demonstrated that the expression of
SOCS3 was associated with the response of CML cells
to IFN-alpha [16, 17], and down-regulation of SOCS3
was a possible reason for imatinib resistance of leukemia
cells [11]. Consistently, in our study, the expression of
SOCS3 in CML cells was up-regulated after imatinib
treatment. Although SOCS3 exerted no remarkable ef-
fect on apoptosis, SOCS3 over-expression could enhance
imatinib-induced apoptosis in CML cells. Takeuchi et al.
suggested increased expression of SOCS3 in bone mar-
row cells may result from the action of several cytokines
secreted in the bone marrow environment [17], so we
speculated the bone marrow environment alteration
caused by imatinib treatment may induce the up-
regulation of SOCS3 in CML cells here. However, the
in-depth mechanism needed to be clarified.
miRNAs play important roles in tumorigenesis [18–
23]. We then explored whether SOCS3 regulated the
growth and chemo-sensitivity of CML cells by modulat-
ing miRNA. The gene expression bead array results indi-
cated that miR-124-3p, a tumor suppressor [24–26], was
significantly affected by SOCS3. Fowler et al demon-
strated that over-expression of miR-124 in GBM cells
was associated with diminished tumor cell migration
and invasion [27]. Moreover, Shi et al. found that miR-
124-3p could inhibit the proliferation of prostate cancer
cells [28]. In our study, we found that miR-124-3p ex-
pression in CML cell lines was regulated by SOCS3. A
significant positive correlation between miR-124-3p and
SOCS3 was observed. And, the inhibitory effect of
SOCS3 on CML cell proliferation was attenuated in the
absence of miR-124-3p. All these data indicated that
miR-124-3p play an important role in SOCS3-mediated
growth inhibition.
Recent study demonstrated that B4GALT1 gene family
play an important role in the resistance of human
leukemia cells to therapeutic drugs. In multidrug resist-
ance leukemia patients, highly expressed B4GALT1 regu-
lated the hedgehog pathway, and were associated with the
expression of p-glycoprotein and multidrug resistance-
Fig. 6 miR-124-3p inhibitor partially neutralized the inhibitory effects of SOCS3. The miR-124-3p inhibitor and control were transduced into K562
and KU812 cells that were stably transduced with SOCS3 over-expression vector. The effects of miR-124-3p on cell growth (a) and colony formation (b)
were determined. Data represented three independent experiments and were shown as the mean ± SD (n = 3), *P < 0.05; compared with empty vector
or inhibitor
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associated protein, resulting in the specific drug-resistant
phenotypes of leukemia cell lines [29, 30]. Here, we first
demonstrated that B4GALT1 was a target gene of miR-
124-3p as predicted by bioinformatics, verified the con-
served region in the B4GALT1 3‘UTR was binding to
miR-124-3p. In addition, we found that B4GALT1 protein
expression was significantly down-regulated by miR-124-
3p over-expression in CML cells. So, we speculated that
SOCS3 enhanced the chemo-sensitivity of CML cells by
down-regulating B4GALT1, and that miR-124-3 was the
link between them. Thus, we analyzed the effect of SOCS3
on the expression of B4GALT1 and proved that SOCS3
modulated the expression of B4GALT1 by miR-124-3p and,
in turn, B4GALT1 could rescue SOCS3-induced chemo-
sensitivity alterations in K562 cells. Finally, tumorigenicity
assays in nude mice confirmed that over-expression of
SOCS3 inhibited the proliferation of K562 cells and down-
regulated the expression of B4GALT1 in vivo. However, the
in vivo function of SOCS-3 after imatinib treatment needs
to be investigated in the further study.
Our results showed SOCS-3 regulated miR-124-3p/
B4GALT1 pathway played an important role in the
Fig. 7 B4GALT1 was a target of miR-124-3p. a Bioinformatics analysis of the predicted interactions of miR-124-3p and its binding sites within the
3’UTR of B4GALT1. b Mutated sequences used in the luciferase assay. c Luciferase analysis in HEK293 cells. The expression levels of miR-124-3p or
B4GALT1 in K562 and KU812 cells were analyzed by qPCR after they were transduced with miR-124-3p expression mimic (d) or inhibitor (e). U6 or
β-Actin was served as an internal control. Each value was the mean ± SD of three experiments (n = 3),*P < 0.05; compared with control or negative
control. f Western blot analysis of B4GALT1 expression in K562 and KU812 cells after they were transduced with miR-124-3p expression mimic or
miR-124-3p inhibitor for 48 h. β-Actin was served as an internal control (n = 3)
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pathogenesis of CML. However, imatinib treatment still
induced miR-124-3p increase in the absence of SOCS3
and SOCS3 could inhibit colony formation, regardless of
the presence of miR-124-3p inhibitor, which implied
other signal pathways may be involved. For example,
previous studies demonstrated JAK/STAT pathway and
cytokine signal pathways were involved in SOCS3-
mediated effects in CML cells [16, 17].
Resistance to targeted drugs remains a challenge for
CML therapy. Accurate biomarkers are of great import-
ance to antitumor therapeutics [31]. In this study, there
was an obvious correlation between SOCS3 expression
and the sensitivity of CML cell lines to imatinib. Thus,
SOCS3 may be used as a novel biomarker predicting the
response to targeted drugs and it was of great value to
further elucidate the role and mechanism underlying
SOCS3 expression in CML cells. However, we did not
explore the role of SOCS3 in primary cells from CML
patients who are resistant to imatinib, and we acknow-
ledge this is a limitation of this study.
Conclusions
In summary, our work revealed that an interesting signal
pathway initiated by SOCS3 was involved in CML
development. Down-regulated SOCS3 in CML cells was
associated with low level of miR-124-3p, then could not
exert enough repressive effect on B4GALT1, resulting in
the proliferation of CML cells and targeted drugs
resistance. In conclusion, SOCS3/miR-124-3p/B4GALT1
signaling pathway plays an important role in the patho-
physiology of CML. SOCS3 may be used as an index for
CML diagnosis, and a novel biomarker predicting the re-
sponse of CML to targeted drugs, in clinical settings.
Methods
Patient samples
BMNCs were obtained from patients with confirmed
diagnose of CML and from healthy donors with in-
formed consent. BMNCs were enriched by Ficoll gradi-
ent centrifugation. The study was performed with the
approval of the Ethics Committee of Chinese PLA Gen-
eral Hospital, Beijing, China.
Cell culture
K562, KU812, HL-60, and BV173 cells were cultured in
RPMI-1640. HEK293 cells were cultured in DMEM.
These mediums contained 10 % (v/v) fetal bovine serum
(Gibco, Life technologies, USA) and 100 mg/mL
Fig. 8 B4GALT1 was regulated by SOCS3/miR-124-3p axis. a Western blot analysis of B4GALT1 expression in K562 cells after SOCS3 up- or down-
regulation. β-Actin was served as an internal control (n = 3). b Western blot analysis of B4GALT1 expression in K562 cells stably expressing SOCS3
after transduction with the miR-124-3p inhibitor or negative control. β-Actin was served as an internal control (n = 3). c Over-expression of
B4GALT1 rescued SOCS3-induced chemo-sensitivity promotion. B4GALT1 expression and control vector were transduced into K562 cells that over-
expressed SOCS3. Apoptosis ratios of K562 cells in different groups were examined by Annexin V assay after imatinib treatment. Data represent the
mean ± SD from three experiments (n = 3). d SOCS3 over-expression inhibited tumor growth of K562 in vivo. *P < 0.05; compared with empty group.
Each point represented the mean of three independent experiments (n = 3). Data are expressed as the mean ± SD. e SOCS3 over-expression inhibited
the expression of B4GALT1 in vivo. B4GALT1 expression in tumors from K562 cells was analyzed by immunohistochemistry
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penicillin/streptomycin. For imatinib treatment, cells
were treated with 1 μmol/L imatinib for 48 h.
Lentiviral plasmid construct and transduction
Lentiviral expression and interference vectors targeting
human SOCS3 were constructed as described previously
[12]. Empty expression vector (empty) or non-targeting
siRNA (shControl) were used as controls of expression
and interference vectors, respectively. Lentiviral particles
were produced and cells were transduced. After transduc-
tion (48 h), positive cells were sorted by fluorescence-
activated cell sorting (FACS), according to the expression
of green fluorescent protein (GFP).
Quantitative RT-PCR
Total RNA isolation, reverse transcription, and the quanti-
fication of target gene expression were performed as previ-
ously described [12]; β-Actin was used as an internal
control. miR-124-3p expression levels were quantified
using U6 as the internal control (GenePharm). The fold-
change in expression was calculated using the following
primer pairs for the amplification of target mRNAs: SOCS3
forward primer 5‘ATCCTGGTGACAT GCTCCTC’3 and
reverse primer 5‘CAAATGTTGCTTCCCCCTTA’3; β-
Actin forward primer 5‘ GATCCACATCTGCTGGAA
GG’3 and reverse primer 5‘AAGTGTGACGTT GAC
ATCCG’3; B4GALT1 forward primer 5‘AACCATGT
GACTGAGTGC CC’3 and reverse primer 5‘TCAG
TGTGTTGTGCCAAAGC’3; Micro124-3p forward primer
5‘TAAGGCACGCGGTGAATGCC’3 and reverse primer
5‘GATTGAATCGA GCACCAG TTAC’3; U6 forward pri-
mer 5‘CGCTTCGGCAG CAC ATATACTA’3 . Unified re-
verse primer 5‘GATTGAATCGA GCACCAG TTAC’3.
Western blot analysis
Cells were lysed directly in lysis buffer to collect whole
cell extracts. Protein samples were separated on poly-
acrylamide gels, transferred onto nitrocellulose mem-
brane by iblot (Invitrogen), detected using horseradish
peroxidase-conjugated secondary antibodies, and ex-
posed to BioMax film (Kodak) following chemilumines-
cence (Santa Cruz, CA, USA). The following primary
antibodies were used: SOCS3, Actin, and B4GALT1
(Santa Cruz, CA, USA).
Cell proliferation assay
Cell proliferation was determined using CCK-8 (Dojindo,
Japan) method. K562 cells (3000 cells/well) were plated
in 96-well plates. At different time points, CCK-8 re-
agents were added to each well and further incubated at
37 °C for 2 h. The number of viable cells was assessed
by measurement of absorbance at 450 nm using a
Multiskan (Thermo Scientific, Asheville, NC, USA).
Clonogenic progenitor cell assay
Cells were seeded in a 6-well plate with methylcellulose
medium (MethoCult H4435, STEMCELL Technologies,
Canada) according to the manufacturer’s instructions.
After 1 week of cultivation, colonies were counted.
Apoptosis assay
The apoptosis assays were performed using the Annexin
V-PE kit (BioLegend, San Diego, CA, USA) according to
the manufacturer’s protocol. The stained cells were im-
mediately analyzed on a FACScalibur flow cytometer
(Becton Dickinson). The data were expressed as the per-
centage of apoptosis cells.
Whole-genome expression analysis
Total RNA was extracted from K562 cells transduced
with over-expression SOCS3 or empty vector (5 × 106
cells) using Trizol reagent (Invitrogen Life Technologies,
Paisley, UK). Genome expression analysis was performed
by Illumina Human HT-12 v4 BeadChip (Illumina, San
Diego, CA, USA) at the Beijing Qian zhao xing ye
Biological Technology Co., Ltd. (Beijing, China).
miR-124-3p mimic and inhibitor
The hsa-miR-124-3p mimic or control sequence, and
hsa-miR-124-3p inhibitor and hsa-miR-124-3p inhibitor
negative control were all purchased from GenePharma
(Shanghai, China).
Luciferase assays
The human pre-miR-124 sequence was amplified and
cloned into pcDNA3.1 constructs (Invitrogen) to gener-
ate the pcDNA3.1-miR-124 expression vector. The full-
length 3‘UTR of B4GALT1 was amplified using cDNA
from K562 cells and double-digested with XbaI/EcoRI
and cloned downstream of the firefly luciferase coding
region sites of a modified pGL3-control plasmid named
Luci-B4GALT1. We also constructed mutated Luci-
B4GALT1 reporter vectors bearing deletions of the UTR
target regions and named them Luci-△B4GALT1. The
vectors were co-transduced with control or pcDNA3.1-
miR-124 expression vectors into K562 cells. Lysates were
prepared 48 h after transduction. Luciferase activity was
measured using a dual-luciferase reporter assay system
(Promega). All experiments were performed in triplicate
at least three independent times.
B4GALT1 expression plasmid construction and transduction
The full-length of the human B4GALT1 sequence was
amplified and cloned into the pcDNA3.1 vector to gen-
erate the B4GALT1 expression vector. K562 cells were
transduced with the B4GALT1 expression vector in 24-
well plates using Lipofectamine 2000 (Invitrogen) ac-
cording to the manufacturer’s protocol.
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Tumorigenicity assays in nude mice
A total of 5 × 106 K562 cells that were stably transduced
with SOCS3 over-expression or empty vectors were
injected into male nude mice subcutaneously (n = 8).
Mice were sacrificed at 28 days post-inoculation, and the
tumors were excised and their weight was measured and
photographed. Tumors from different groups were re-
moved and fixed with formaldehyde, embedded in paraf-
fin wax, and sectioned. The sections were cleared
through xylene, graded ethanol, water and incubated
with anti-B4GALT1 antibodies (Santa Cruz) at 4 °C
overnight, stained with DAPI, washed with PBS three
times, and observed by fluorescence microscopy.
Statistical analysis
All data were expressed as the mean ± standard devi-
ation (SD). The differences between two groups were
assessed by Student’s t test. Pearson’s correlation coeffi-
cient was calculated to analyze the correlation. P < 0.05
was considered to be statistically significant.
Additional files
Additional file 1: Figure S1. Expression of SOCS3 protein in CML cells.
SOCS3 expression in CML cell lines and BMNCs from CML patients was
analyzed by Western blotting. β-Actin was served as an internal control
(n = 3). (TIF 69 kb)
Additional file 2: Figure S2. GO analysis of SOCS3-induced gene
expression alteration in K562 cells. Branches of the GO hierarchical tree
with significantly enriched GO terms were indicated in red boxes.
Insignificant GO terms within the hierarchical tree are shown as white
boxes. (TIF 203 kb)
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